Coastal Infusion Administers Adakveo
| J-Code | J0791 |
|---|---|
| Manufacturer | Novartis |
| First Approved | 11/15/2019 |
Coastal Infusion can administer your Adakveo prescription at any of our south Florida locations.
Adakveo (crizanlizumab-tmca) is used to treat pain crises associated with sickle cell disease (“vaso-occlusive crises”).
The active substance in Adakveo, crizanlizumab, is a monoclonal antibody designed to attach to a substance, P-selectin, present on the surface of the cells lining blood vessels. P-selectin causes cells to stick to the blood vessels, which plays a role in clogging up the vessels during sickle cell disease.
By attaching to and blocking the action of P-selectin, the medicine helps reduce the formation of clumps of sickle cells and improve blood flow.
What It Treats
Adakveo is used to treat pain crises associated with sickle cell disease.
Prescribed By
Adakveo is most often prescribed by Hematologists.
How it’s Administered
Adakveo is administered by intravenous infusion. Adakveo infusions take about 30 minutes.
Frequency
Once every 4 weeks for RA, more frequently for other diagnoses.
Additional Resources
The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies